November 14, 2023

Dear Rett Patient Advocacy Leaders,

We are writing to share a series of updates that Taysha provided in a press release today. Please find a summary of these updates below, as well as a list of answers to some frequently asked questions.

- Taysha shared early, interim data from the first two adult participants who were dosed with the investigational gene therapy, TSHA-102, in the REVEAL Adult Study
- Dosing of the third adult participant in the REVEAL Adult Study in Canada is expected to take place in the fourth quarter of 2023/first quarter of 2024
- Dosing of the first pediatric participant in the REVEAL Pediatric Study in the United States (U.S.) is expected to take place in the first quarter of 2024

What is the REVEAL Adult Study?

- The REVEAL Adult Study is a Phase 1/2 clinical trial designed to evaluate whether TSHA-102, the investigational gene therapy, is safe, whether it is tolerable, and whether there may be beneficial effects in adult females 18 years and older with Rett syndrome
- The study is also designed to evaluate two different dose levels to determine the optimal amount (highest tolerable dose) of TSHA-102
- The study is currently being conducted at CHU Sainte-Justine, the Université de Montréal mother and Child University Hospital Centre in Montreal, Canada

How many participants have been dosed in the REVEAL Adult Study to date?

- Two participants have been dosed with the TSHA-102 at the first dose level

When will the third participant be dosed in the REVEAL Adult Study?

- The Independent Data Monitoring Committee (IDMC) provided clearance to proceed with dosing a third participant based on available data
- Dosing is expected in the fourth quarter of 2023/first quarter of 2024 and will complete the low-dose cohort of the study

What are the early, interim findings from the first two participants dosed with TSHA-102 in the REVEAL Adult Study?

It is important to note that we cannot make any conclusions on interim findings of a clinical trial until all enrolled subjects are dosed and evaluated for the duration of the study, and once all the data has been collected and analyzed. Making conclusions about interim data may not accurately predict the full risk/benefit profile of an investigational product.

- There were no treatment-emergent serious adverse events (SAEs) related to TSHA-102 as of 20 weeks following administration of TSHA-102 in the first participant dosed and no treatment-emergent SAEs as of six weeks following administration of TSHA-102 in the second participant dosed
- Both participants have shown initial improvements based on data collected from clinician- and caregiver-reported assessments at the 12-week (participant one) and four-week (participant two) time points following administration of TSHA-102

Is the REVEAL Adult Study still enrolling participants in Canada?

- The REVEAL Adult Study is actively enrolling adult females 18 years and older with Rett syndrome
- The study is being conducted in Montreal, Canada
- More details about the clinical trial are available at: https://clinicaltrials.gov/study/NCT05606614

What are Taysha's plans for a clinical trial for females with Rett syndrome in the United States (U.S.)?

- The first clinical trial in the U.S. is called the REVEAL Pediatric Study and will study TSHA-102 in female children 5-8 years old, with plans to expand to female children 3-8 years old in future phases of the study
- Additional details about the clinical trial, including inclusion and exclusion criteria, number of participants and study site locations, will be shared soon
- Dosing of the first pediatric participant in the REVEAL Pediatric Study in the U.S. is expected in the first quarter of 2024

What are Taysha's plans for a clinical trial for females with Rett syndrome in the United Kingdom (UK)?

- Taysha submitted a clinical trial application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) to study TSHA-102 in female children with Rett syndrome and expects to receive MHRA feedback by year-end 2023

How can families or caregivers contact someone at Taysha?

- If families or caregivers would like to connect with someone from the Taysha Patient Affairs team, please contact patientaffairs@tayshagtx.com

We would like to thank the entire Rett community and the Rett patient advocacy groups for your continued partnership. We would also like to acknowledge the individuals and families participating in the trial for contributing to this important research to better understand the potential of gene therapy for Rett syndrome.

We look forward to sharing more information as it is publicly available.

Sincerely,
The Taysha Patient Affairs Team